請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5122
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳韻如(Yun-Ru (Ruby) | |
dc.contributor.author | Yi-Hung Liao | en |
dc.contributor.author | 廖宜鴻 | zh_TW |
dc.date.accessioned | 2021-05-15T17:52:12Z | - |
dc.date.available | 2014-08-17 | |
dc.date.available | 2021-05-15T17:52:12Z | - |
dc.date.copyright | 2014-08-17 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-12 | |
dc.identifier.citation | Reference
1. Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of Alzheimer’s 1907 paper, ‘Uber eine eigenartige Erkankung der Hirnrinde’. Clin Anat 8, 429–431 (1995). 2. Alzheimer’s News 1/17/2014 | Alzheimer’s Association. at <http://www.alz.org/news_and_events_law_by_obama.asp> 3. Abbott, A. Dementia: A problem for our age. Nature 475, S2–S4 (2011). 4. Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H. M. Forecasting the global burden of Alzheimer’s disease. Alzheimer’s & Dementia 3, 186–191 (2007). 5. Mattson, M. P. Pathways towards and away from Alzheimer’s disease. Nature 430, 631–639 (2004). 6. 2014 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia 10, e47–e92 (2014). 7. Lindsay, J. et al. Risk Factors for Alzheimer’s Disease: A Prospective Analysis from the Canadian Study of Health and Aging. Am. J. Epidemiol. 156, 445–453 (2002). 8. Tanzi, R. E. & Bertram, L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 120, 545–55 (2005). 9. Jellinger, K. Head injury and dementia. Current Opinion in Neurology December 2004 17, 719–723 (2004). 10. Simons, M., Keller, P., Dichgans, J. & Schulz, J. B. Cholesterol and Alzheimer’s disease: is there a link? Neurology 57, 1089–1093 (2001). 11. Florent-Béchard, S. et al. The essential role of lipids in Alzheimer’s disease. Biochimie 91, 804–809 (2009). 12. Van Echten-Deckert, G. & Walter, J. Sphingolipids: Critical players in Alzheimer’s disease. Progress in Lipid Research 51, 378–393 (2012). 13. Biessels, G. J. & Kappelle, L. J. Increased risk of Alzheimer’s disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochemical Society Transactions 33, 1041 (2005). 14. Hölscher, C. Diabetes as a risk factor for Alzheimer’s disease: insulin signalling impairment in the brain as an alternative model of Alzheimer’s disease. Biochemical Society Transactions 39, 891–897 (2011). 15. Zatta, P., Drago, D., Bolognin, S. & Sensi, S. L. Alzheimer’s disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 30, 346–55 (2009). 16. Duce, J. A. & Bush, A. I. Biological metals and Alzheimer’s disease: implications for therapeutics and diagnostics. Prog Neurobiol 92, 1–18 (2010). 17. Amadoruge, P. C. & Barnham, K. J. Alzheimer’s disease and metals: a review of the involvement of cellular membrane receptors in metallosignalling. Int J Alzheimers Dis 2011, 542043 (2011). 18. Roberts, B. R., Ryan, T. M., Bush, A. I., Masters, C. L. & Duce, J. A. The role of metallobiology and amyloid-beta peptides in Alzheimer’s disease. J Neurochem 120 Suppl 1, 149–66 (2012). 19. Lovell, M. ., Robertson, J. ., Teesdale, W. ., Campbell, J. . & Markesbery, W. . Copper, iron and zinc in Alzheimer’s disease senile plaques. Journal of the Neurological Sciences 158, 47–52 (1998). 20. Kepp, K. P. Bioinorganic Chemistry of Alzheimer’s Disease. Chem. Rev. 112, 5193–5239 (2012). 21. Ballard, C. et al. Alzheimer’s disease. Lancet 377, 1019–31 (2011). 22. Lemere, C. A. & Masliah, E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat Rev Neurol 6, 108–119 (2010). 23. Delrieu, J., Ousset, P. J., Caillaud, C. & Vellas, B. ‘Clinical trials in Alzheimer’s disease’: immunotherapy approaches. J. Neurochem. 120 Suppl 1, 186–193 (2012). 24. Ritchie CW, Bush AI, Mackinnon A & et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting aβ amyloid deposition and toxicity in alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685–1691 (2003). 25. Bush, A. I. Drug development based on the metals hypothesis of Alzheimer’s disease. J. Alzheimers Dis. 15, 223–240 (2008). 26. Lannfelt, L. et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. The Lancet Neurology 7, 779–786 (2008). 27. Bulic, B. et al. Development of tau aggregation inhibitors for Alzheimer’s disease. Angew. Chem. Int. Ed. Engl. 48, 1740–1752 (2009). 28. Wischik, C. M., Harrington, C. R. & Storey, J. M. D. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem. Pharmacol. 88, 529–539 (2014). 29. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. Journal of Molecular Biology 273, 729–739 (1997). 30. Klunk, W. E., Jacob, R. F. & Mason, R. P. in Methods in Enzymology (ed. Ronald Wetzel) Volume 309, 285–305 (Academic Press, 1999). 31. Naiki, H., Higuchi, K., Hosokawa, M. & Takeda, T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Analytical Biochemistry 177, 244–249 (1989). 32. Tycko, R. & Wickner, R. B. Molecular Structures of Amyloid and Prion Fibrils: Consensus versus Controversy. Acc. Chem. Res. 46, 1487–1496 (2013). 33. Hardy, J. & Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol. Sci. 12, 383–388 (1991). 34. Huang, X., Moir, R. D., Tanzi, R. E., Bush, A. I. & Rogers, J. T. Redox-Active Metals, Oxidative Stress, and Alzheimer’s Disease Pathology. Annals of the New York Academy of Sciences 1012, 153–163 (2004). 35. Sofic, E. et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transmission 74, 199–205 (1988). 36. Schrag, M., Mueller, C., Oyoyo, U., Smith, M. A. & Kirsch, W. M. Iron, zinc and copper in the Alzheimer’s disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Progress in Neurobiology 94, 296–306 (2011). 37. Zhu, X., Raina, A. K., Perry, G. & Smith, M. A. Alzheimer’s disease: the two-hit hypothesis. The Lancet Neurology 3, 219–226 (2004). 38. Zhu, X., Lee, H., Perry, G. & Smith, M. A. Alzheimer disease, the two-hit hypothesis: An update. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1772, 494–502 (2007). 39. Shen, J. & Kelleher, R. J., 3rd. The presenilin hypothesis of Alzheimer’s disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104, 403–9 (2007). 40. Kang, J. et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733–736 (1987). 41. Thinakaran, G. & Koo, E. H. Amyloid Precursor Protein Trafficking, Processing, and Function. J. Biol. Chem. 283, 29615–29619 (2008). 42. Vingtdeux, V., Sergeant, N. & Buee, L. Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer’s disease. Front. Physio. 3, 229 (2012). 43. Francis, R. et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3, 85–97 (2002). 44. Bibl, M. et al. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. Journal of Neurochemistry 103, 467–474 (2007). 45. Schoonenboom, N. S. et al. Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same? Ann Neurol. 58, 139–142 (2005). 46. Burdick, D. et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J. Biol. Chem. 267, 546–554 (1992). 47. Jarrett, J. T., Berger, E. P. & Lansbury, P. T. The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 4693–4697 (1993). 48. Riek, R., Güntert, P., Döbeli, H., Wipf, B. & Wüthrich, K. NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, Aβ(1–40)ox and Aβ(1–42)ox. European Journal of Biochemistry 268, 5930–5936 (2001). 49. Petkova, A. T. et al. A structural model for Alzheimer’s β-amyloid fibrils based on experimental constraints from solid state NMR. PNAS 99, 16742–16747 (2002). 50. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101–12 (2007). 51. Jan, A., Gokce, O., Luthi-Carter, R. & Lashuel, H. A. The Ratio of Monomeric to Aggregated Forms of Aβ40 and Aβ42 Is an Important Determinant of Amyloid-β Aggregation, Fibrillogenesis, and Toxicity. J. Biol. Chem. 283, 28176–28189 (2008). 52. Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. U.S.A. 108, 5819–5824 (2011). 53. Kayed, R. et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science 300, 486–489 (2003). 54. Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95, 6448–6453 (1998). 55. Barghorn, S. et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer’s disease. J. Neurochem. 95, 834–847 (2005). 56. Nimmrich, V. et al. Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J. Neurosci. 28, 788–797 (2008). 57. Lasagna-Reeves, C. A., Glabe, C. G. & Kayed, R. Amyloid-beta Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain. J Biol Chem 286, 22122–30 (2011). 58. Lesné, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352–357 (2006). 59. Paranjape, G. S., Gouwens, L. K., Osborn, D. C. & Nichols, M. R. Isolated Amyloid-β(1–42) Protofibrils, But Not Isolated Fibrils, Are Robust Stimulators of Microglia. ACS Chem. Neurosci. 3, 302–311 (2012). 60. Dahlgren, K. N. et al. Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability. J. Biol. Chem. 277, 32046–32053 (2002). 61. Petkova, A. T. et al. Self-Propagating, Molecular-Level Polymorphism in Alzheimer’s ß-Amyloid Fibrils. Science 307, 262–265 (2005). 62. Manna, M. & Mukhopadhyay, C. Binding, Conformational Transition and Dimerization of Amyloid-β Peptide on GM1-Containing Ternary Membrane: Insights from Molecular Dynamics Simulation. PLoS ONE 8, e71308 (2013). 63. Hou, L. et al. Solution NMR Studies of the Aβ(1−40) and Aβ(1−42) Peptides Establish that the Met35 Oxidation State Affects the Mechanism of Amyloid Formation. J. Am. Chem. Soc. 126, 1992–2005 (2004). 64. Chen, Y.-R. & Glabe, C. G. Distinct Early Folding and Aggregation Properties of Alzheimer Amyloid-β Peptides Aβ40 and Aβ42 STABLE TRIMER OR TETRAMER FORMATION BY Aβ42. J. Biol. Chem. 281, 24414–24422 (2006). 65. Ni, C.-L., Shi, H.-P., Yu, H.-M., Chang, Y.-C. & Chen, Y.-R. Folding stability of amyloid-β 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB J 25, 1390–1401 (2011). 66. Lazo, N. D., Grant, M. A., Condron, M. C., Rigby, A. C. & Teplow, D. B. On the nucleation of amyloid β-protein monomer folding. Protein Science 14, 1581–1596 (2005). 67. Grant, M. A. et al. Familial Alzheimer’s disease mutations alter the stability of the amyloid β-protein monomer folding nucleus. PNAS 104, 16522–16527 (2007). 68. Harper, J. D. & Lansbury, P. T., Jr. Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66, 385–407 (1997). 69. Roychaudhuri, R., Yang, M., Hoshi, M. M. & Teplow, D. B. Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284, 4749–53 (2009). 70. Luhrs, T. et al. 3D structure of Alzheimer’s amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A 102, 17342–7 (2005). 71. Tycko, R. Molecular structure of amyloid fibrils: insights from solid-state NMR. Quarterly Reviews of Biophysics 39, 1–55 (2006). 72. Petkova, A. T., Yau, W.-M. & Tycko, R. Experimental constraints on quaternary structure in Alzheimer’s beta-amyloid fibrils. Biochemistry 45, 498–512 (2006). 73. Bonda, D. J. et al. Role of metal dyshomeostasis in Alzheimer’s disease. Metallomics 3, 267–270 (2011). 74. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L. & Markesbery, W. R. Copper, iron and zinc in Alzheimer’s disease senile plaques. Journal of the Neurological Sciences 158, 47–52 (1998). 75. Bush, A. I. The metallobiology of Alzheimer’s disease. Trends in Neurosciences 26, 207–214 (2003). 76. Faller, P., Hureau, C. & Berthoumieu, O. Role of Metal Ions in the Self-assembly of the Alzheimer’s Amyloid-β Peptide. Inorg. Chem. 52, 12193–12206 (2013). 77. Stellato, F. et al. Metal binding in amyloid β-peptides shows intra- and inter-peptide coordination modes. Eur Biophys J 35, 340–351 (2006). 78. Sarell, C. J., Syme, C. D., Rigby, S. E. J. & Viles, J. H. Copper(II) Binding to Amyloid-β Fibrils of Alzheimer’s Disease Reveals a Picomolar Affinity: Stoichiometry and Coordination Geometry Are Independent of Aβ Oligomeric Form. Biochemistry 48, 4388–4402 (2009). 79. Shin, B. & Saxena, S. Direct Evidence That All Three Histidine Residues Coordinate to Cu(II) in Amyloid-β1−16+. Biochemistry 47, 9117–9123 (2008). 80. Dorlet, P., Gambarelli, S., Faller, P. & Hureau, C. Pulse EPR Spectroscopy Reveals the Coordination Sphere of Copper(II) Ions in the 1–16 Amyloid-β Peptide: A Key Role of the First Two N-Terminus Residues. Angewandte Chemie International Edition 48, 9273–9276 (2009). 81. Smith, D. P. et al. Copper-mediated Amyloid-β Toxicity Is Associated with an Intermolecular Histidine Bridge. J. Biol. Chem. 281, 15145–15154 (2006). 82. Syme, C. D. & Viles, J. H. Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Aβ) of Alzheimer’s disease. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1764, 246–256 (2006). 83. Curtain, C. C. et al. Alzheimer’s Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits. J. Biol. Chem. 276, 20466–20473 (2001). 84. Minicozzi, V. et al. Identifying the Minimal Copper- and Zinc-binding Site Sequence in Amyloid-β Peptides. J. Biol. Chem. 283, 10784–10792 (2008). 85. Tsvetkov, P. O. et al. Minimal Zn2+ Binding Site of Amyloid-β. Biophysical Journal 99, L84–L86 (2010). 86. Nair, N. G., Perry, G., Smith, M. A. & Reddy, V. P. NMR Studies of Zinc, Copper, and Iron Binding to Histidine, the Principal Metal Ion Complexing Site of Amyloid-β Peptide. Journal of Alzheimer’s Disease 20, 57–66 (2010). 87. Bertram, L. The genetic epidemiology of neurodegenerative disease. Journal of Clinical Investigation 115, 1449–1457 (2005). 88. Benilova, I., Karran, E. & De Strooper, B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci 15, 349–357 (2012). 89. Xu, L., Shan, S. & Wang, X. Single Point Mutation Alters the Microstate Dynamics of Amyloid β-Protein Aβ42 as Revealed by Dihedral Dynamics Analyses. J. Phys. Chem. B 117, 6206–6216 (2013). 90. Baumketner, A., Krone, M. G. & Shea, J.-E. Role of the familial Dutch mutation E22Q in the folding and aggregation of the 15–28 fragment of the Alzheimer amyloid-β protein. PNAS 105, 6027–6032 (2008). 91. Hori, Y. et al. The Tottori (D7N) and English (H6R) Familial Alzheimer Disease Mutations Accelerate Aβ Fibril Formation without Increasing Protofibril Formation. J. Biol. Chem. 282, 4916–4923 (2007). 92. Chen, W.-T. et al. Amyloid-Beta (Aβ) D7H Mutation Increases Oligomeric Aβ42 and Alters Properties of Aβ-Zinc/Copper Assemblies. PLoS ONE 7, e35807 (2012). 93. Alies, B. et al. pH-Dependent Cu(II) Coordination to Amyloid-β Peptide: Impact of Sequence Alterations, Including the H6R and D7N Familial Mutations. Inorg. Chem. 50, 11192–11201 (2011). 94. Jonsson, T. et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488, 96–99 (2012). 95. Fede, G. D. et al. A Recessive Mutation in the APP Gene with Dominant-Negative Effect on Amyloidogenesis. Science 323, 1473–1477 (2009). 96. Drew, S. C., Masters, C. L. & Barnham, K. J. Alzheimer’s Aβ Peptides with Disease-Associated N-Terminal Modifications: Influence of Isomerisation, Truncation and Mutation on Cu2+ Coordination. PLoS ONE 5, e15875 (2010). 97. Mout, R., Moyano, D. F., Rana, S. & Rotello, V. M. Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev 41, 2539–44 (2012). 98. Kim, S. T., Saha, K., Kim, C. & Rotello, V. M. The Role of Surface Functionality in Determining Nanoparticle Cytotoxicity. Acc. Chem. Res. 46, 681–691 (2013). 99. Sapsford, K. E. et al. Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology. Chem. Rev. 113, 1904–2074 (2013). 100. Mirkin, C. A. et al. Gold Nanoparticles for Biology and Medicine. Angewandte Chemie-International Edition 49, 3280–3294 (2010). 101. Kumar, A., Zhang, X. & Liang, X.-J. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol. Adv. 31, 593–606 (2013). 102. Parveen, S., Misra, R. & Sahoo, S. K. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine: Nanotechnology, Biology and Medicine 8, 147–166 (2012). 103. Doane, T. L. & Burda, C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem Soc Rev 41, 2885–2911 (2012). 104. Khandelia, R., Jaiswal, A., Ghosh, S. S. & Chattopadhyay, A. Nanocarriers: Gold Nanoparticle–Protein Agglomerates as Versatile Nanocarriers for Drug Delivery (Small 20/2013). Small 9, 3493–3493 (2013). 105. Murphy, C. J. et al. Gold nanoparticles in biology: beyond toxicity to cellular imaging. Acc Chem Res 41, 1721–30 (2008). 106. Psarros, C., Lee, R., Margaritis, M. & Antoniades, C. Nanomedicine for the prevention, treatment and imaging of atherosclerosis. Nanomedicine 8 Suppl 1, S59–68 (2012). 107. Doll, T. A. P. F., Raman, S., Dey, R. & Burkhard, P. Nanoscale assemblies and their biomedical applications. J. R. Soc. Interface 10, (2013). 108. Brambilla, D. et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine: Nanotechnology, Biology and Medicine 7, 521–540 (2011). 109. Boer, D. A. G. de & Gaillard, P. J. Strategies to Improve Drug Delivery Across the Blood-Brain Barrier. Clin Pharmacokinet 46, 553–576 (2007). 110. Jain, K. K. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis 4, 287–291 (2007). 111. Modi, G. et al. Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 88, 272–85 (2009). 112. Sahni, J. K. et al. Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Control Release 152, 208–31 (2011). 113. Goldsmith, M., Abramovitz, L. & Peer, D. Precision Nanomedicine in Neurodegenerative Diseases. ACS Nano 8, 1958–1965 (2014). 114. Cherny, R. A. et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer’s Disease Transgenic Mice. Neuron 30, 665–676 (2001). 115. Härtig, W. et al. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer’s disease. Neuroscience Letters 338, 174–176 (2003). 116. Kogan, M. J. et al. Nanoparticle-Mediated Local and Remote Manipulation of Protein Aggregation. Nano Lett. 6, 110–115 (2006). 117. Song, Q. et al. Lipoprotein-Based Nanoparticles Rescue the Memory Loss of Mice with Alzheimer’s Disease by Accelerating the Clearance of Amyloid-Beta. ACS Nano (2014). doi:10.1021/nn4058215 118. Edelhoch, H. Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6, 1948–54 (1967). 119. Cabaleiro-Lago, C. et al. Inhibition of amyloid beta protein fibrillation by polymeric nanoparticles. J Am Chem Soc 130, 15437–43 (2008). 120. Yoo, S. I. et al. Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles: Functional Similarities with Proteins. Angew. Chem. Int. Ed. 50, 5110–5115 (2011). 121. Brambilla, D. et al. Colloidal properties of biodegradable nanoparticles influence interaction with amyloid-β peptide. Journal of Biotechnology 156, 338–340 (2011). 122. Zhang, D. et al. Gold nanoparticles can induce the formation of protein-based aggregates at physiological pH. Nano Letters 9, 666–71 (2009). 123. LeVine III, H. in Methods in Enzymology (ed. Ronald Wetzel) Volume 309, 274–284 (Academic Press, 1999). 124. Biancalana, M. & Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim. Biophys. Acta 1804, 1405–1412 (2010). 125. Nilsson, M. R. Techniques to study amyloid fibril formation in vitro. Methods 34, 151–160 (2004). 126. Krebs, M. R. H., Morozova-Roche, L. A., Daniel, K., Robinson, C. V. & Dobson, C. M. Observation of sequence specificity in the seeding of protein amyloid fibrils. Protein Science 13, 1933–1938 (2004). 127. Johan, K. et al. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. PNAS 95, 2558–2563 (1998). 128. Suzuki, N. et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336–1340 (1994). 129. Frost, D., Gorman, P. M., Yip, C. M. & Chakrabartty, A. Co-incorporation of Aβ40 and Aβ42 to form mixed pre-fibrillar aggregates. European Journal of Biochemistry 270, 654–663 (2003). 130. Kulic, L. et al. Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation. Transl Psychiatry 2, e183 (2012). 131. Natalello, A., Ami, D. & Doglia, S. M. in Intrinsically Disordered Protein Analysis (eds. Uversky, V. N., Dunker, A. K. & Walker, J. M.) 895, 229–244 (Humana Press, 2012). 132. Mohanty, J., Choudhury, S. D., Pal, H. & Bhasikuttan, A. C. Early detection of insulin fibrillation: a fluorescence lifetime assay to probe the pre-fibrillar regime. Chem. Commun. 48, 2403–2405 (2012). 133. Chen, W.-T., Liao, Y.-H., Yu, H.-M., Cheng, I. H. & Chen, Y.-R. Distinct Effects of Zn2+, Cu2+, Fe3+, and Al3+ on Amyloid-β Stability, Oligomerization, and Aggregation AMYLOID-β DESTABILIZATION PROMOTES ANNULAR PROTOFIBRIL FORMATION. J. Biol. Chem. 286, 9646–9656 (2011). 134. Alies, B. et al. Cu(II) Affinity for the Alzheimer’s Peptide: Tyrosine Fluorescence Studies Revisited. Anal. Chem. 85, 1501–1508 (2013). 135. Kremer, J. J., Pallitto, M. M., Sklansky, D. J. & Murphy, R. M. Correlation of β-Amyloid Aggregate Size and Hydrophobicity with Decreased Bilayer Fluidity of Model Membranes+. Biochemistry 39, 10309–10318 (2000). 136. Bolognesi, B. et al. ANS Binding Reveals Common Features of Cytotoxic Amyloid Species. ACS Chem. Biol. 5, 735–740 (2010). 137. Teplow, D. B. Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol 413, 20–33 (2006). 138. Syme, C. D., Nadal, R. C., Rigby, S. E. J. & Viles, J. H. Copper Binding to the Amyloid-β (Aβ) Peptide Associated with Alzheimer’s Disease FOLDING, COORDINATION GEOMETRY, pH DEPENDENCE, STOICHIOMETRY, AND AFFINITY OF Aβ-(1–28): INSIGHTS FROM A RANGE OF COMPLEMENTARY SPECTROSCOPIC TECHNIQUES. J. Biol. Chem. 279, 18169–18177 (2004). 139. Hou, L. & Zagorski, M. G. NMR Reveals Anomalous Copper(II) Binding to the Amyloid Aβ Peptide of Alzheimer’s Disease. J. Am. Chem. Soc. 128, 9260–9261 (2006). 140. Biancalana, M. & Koide, S. Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta 1804, 1405–12 (2010). 141. Cabaleiro-Lago, C., Quinlan-Pluck, F., Lynch, I., Dawson, K. A. & Linse, S. Dual Effect of Amino Modified Polystyrene Nanoparticles on Amyloid beta Protein Fibrillation. Acs Chemical Neuroscience 1, 279–287 (2010). 142. Kim, J. E. & Lee, M. Fullerene inhibits beta-amyloid peptide aggregation. Biochem Biophys Res Commun 303, 576–9 (2003). 143. Wagner, S. C. et al. Nanoparticle-induced folding and fibril formation of coiled-coil-based model peptides. Small 6, 1321–8 (2010). 144. Linse, S. et al. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci U S A 104, 8691–6 (2007). 145. Alvarez-Puebla, R. A., Arceo, E., Goulet, P. J., Garrido, J. J. & Aroca, R. F. Role of nanoparticle surface charge in surface-enhanced Raman scattering. J Phys Chem B 109, 3787–92 (2005). 146. Olmedo, I. et al. How changes in the sequence of the peptide CLPFFD-NH2 can modify the conjugation and stability of gold nanoparticles and their affinity for beta-amyloid fibrils. Bioconjug Chem 19, 1154–63 (2008). 147. Yoshiike, Y., Akagi, T. & Takashima, A. Surface Structure of Amyloid-β Fibrils Contributes to Cytotoxicity. Biochemistry 46, 9805–9812 (2007). 148. Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15, 558–566 (2008). 149. Sonavane, G., Tomoda, K. & Makino, K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces 66, 274–80 (2008). 150. Stsiapura, V. I. et al. Thioflavin T as a Molecular Rotor: Fluorescent Properties of Thioflavin T in Solvents with Different Viscosity. J. Phys. Chem. B 112, 15893–15902 (2008). 151. Mohanty, J., Choudhury, S. D., Pal, H. & Bhasikuttan, A. C. Early detection of insulin fibrillation: a fluorescence lifetime assay to probe the pre-fibrillar regime. Chem. Commun. 48, 2403–2405 (2012). 152. Danielsson, J., Pierattelli, R., Banci, L. & Gräslund, A. High-resolution NMR studies of the zinc-binding site of the Alzheimer’s amyloid β-peptide. FEBS Journal 274, 46–59 (2007). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5122 | - |
dc.description.abstract | 類澱粉蛋白斑塊是許多神經退化性疾病的病徵。斑塊的主要成分是乙型類澱粉蛋白,其纖維化目前被接受是造成阿茲海默症的致病原因。然而,乙型類澱粉蛋白的致病性的調控機制至今仍未有全盤的理解,也未有一致的結論。我們在三個章節中探討三個與乙型類澱粉蛋白有關的主題。第一個主題,我們嘗試了解奈米尺度的金粒子是否影響乙型類澱粉蛋白的纖維化過程及形成此影響的原因。實驗結果顯示未經過表面修飾的裸奈米金粒子能以與劑量呈正相關的方式抑制乙型類澱粉蛋白的纖維化,並造成其形成斷裂的類澱粉蛋白纖維與球型多倍體。我們亦發現裸奈米金粒子偏好附著於纖維而非無定型的堆積。此外,奈米金粒子表面的負電位對於其對乙型類澱粉蛋白纖維化的抑制作用有關鍵性的影響。我們的合作人員亦提供細胞毒性測試結果,顯示經過奈米金粒子抑制後的乙型類澱粉蛋白的最終產物對神經細胞的毒性較低。
第二個主題中,我們欲瞭解與家族性遺傳阿茲海默症有關的E22及D23單點突變如何影響同源聚合與異源聚合形成之類澱粉蛋白纖維結構。在我們實驗中,同源聚合指的是單一來源的乙型類澱粉蛋白經培養後形成之纖維,而異源聚合則是混合同濃度之兩種不同乙型類澱粉蛋白 (原生型與突變型) 再經培養後形成的類澱粉蛋白纖維。實驗結果發現同源聚合纖維在蛋白質二級結構上與異源聚合纖維有顯著的不同。而此二集結構上的相異並未反應在類澱粉蛋白纖維螢光探測分子 Thioflavin T與纖維結合的反應計量上。然而,透過ThT與類澱粉蛋白纖維結合後的螢光壽命的測量卻可以得知此參數可能能夠反應纖維結構的異同。我們尚在進行更多相關的實驗以佐證目前實驗結果的初步結論。 我們在最後一個主題探討過渡型金屬離子,特別是二價銅離子與鋅離子,與乙型類澱粉蛋白的交互作用細節及另幾類家族性遺傳相關的 H6及D7單點突變如何影響這交互作用。首先我們提供鋅、銅、鐵、鋁離子與原生型乙型類澱粉蛋白的豪秒級結合動力學,結果顯示這四種金屬離子與乙型類澱粉蛋白結合的速度有顯著差異。接著我們專注於另一類家族性遺傳阿茲海默症變異型H6和D7對於銅離子與乙型類澱粉蛋白結合的影響。實驗結果顯示,除了D7A和H6R外,銅離子結合伴隨著表面疏水性區域的減少。核磁共振實驗結果表明在未加金屬離子前,變異型與原生型乙型類澱粉蛋白在芳香族支鏈光譜區域,特別是H6, H13/H14,和Y10,有些微差異。銅離子結合而導致的光譜消失在D7H變異型中較為不顯著。1H-15N異核核磁共振光譜顯示銅離子與D7H和原生型乙型類澱粉蛋白結合的相異之處。 | zh_TW |
dc.description.abstract | Amyloid plagues are the major pathogenic hallmarks in many neurodegenerative diseases. Fibrillization of the primary constituents, amyloid-β (Aβ), in plagues is considered the pathogenesis of Alzheimer’s disease (AD). Conclusive evidence is still lacking to reach a comprehensive and convergent view of how Aβ is modulated in the pathogenesis of AD. Here, in three separate chapters, we examined how gold nanoparticles (AuNPs) interfere with fibrillization of Aβ, the effects of single-point N-terminal mutation, H6 and D7, on the interactions between metal ions and Aβ, and how single-point mutations, E22 and D23, influence the structures of fibril.
In Chapter 3, experimental results showed that (1) bare AuNPs inhibited Aβ fibrillization in a dose-dependent manner and redirected Aβ forming fragmented fibrils and spherical oligomers; (2) bare AuNPs bound preferentially to Aβ fibrils but not amorphous aggregates; (3) negative surface potential of AuNPs was required for inhibitive effect. In conjunction with our in vitro biophysical and biochemical data, cell studies from our lab member revealed that in our experimental settings, inhibition of Aβ fibrillization by negatively charged AuNPs also reduce Aβ-induced cytotoxicity in neuronal cells. In Chapter 4, we aimed to reveal distinctions among structures of homopolymeric fibrils (homo-fibrils) formed from incubation of monomers of a single species, and heteropolymeric ones (hetero-fibrils) started from incubation of equal-molar-mixed monomers of wild type and an Aβ variant. We showed that E22 hetero-fibrils are distinct from E22 homo-fibrils in terms of secondary structures. Perturbed secondary structure could influence conformational packing of cross β-sheet, which were not revealed by stoichiometry between Aβ and ThT but by ThT fluorescence lifetime. In Chapter 5, we investigated millisecond binding kinetics of four metal ions, Zn2+, Cu2+, Fe3+, and Al3+. We then focused on Cu2+ and demonstrated that mutation at residues H6 and D7 impact on Cu2+ binding affinities. We found by Bis-ANS fluorescence that diminished hydrophobic exposure was accompanied by Cu2+ binding except for D7A and H6R. Our preliminary proton NMR showed that there existed environmental variance surrounding residues H6, H13/H14, and Y10 among monomeric Aβ variants in native condition. Cu2+-binding-induced peak loss was less evident in D7 mutants. 1H-15N NMR HSQC spectroscopy provided additional information regarding the residual involvement on Cu2+ binding between D7H and wild type Aβ. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:52:12Z (GMT). No. of bitstreams: 1 ntu-103-D96B46015-1.pdf: 4324030 bytes, checksum: 2afd98d5f7efe60c9e3a84f35625cf37 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Table of Contents
口試委員會審定書 .i 誌謝........... ii 中文摘要...... iv Abstract...... vi Abbreviations viii Table of Contents x List of Figures xiv List of Tables xviii Chapter 1 Introduction 1 1.1 Alzheimer’s disease 1 1.1.1 Overview 1 1.1.2 Risk factors and treatments 3 1.1.3 Hypotheses of the pathogenesis of Alzheimer’s Disease 4 1.2 Amyloid-β 5 1.2.1 Amyloid-β monomer 8 1.2.2 Amyloid-β fibrils 9 1.3 Amyloid-β and metal ions 11 1.4 Single-point mutations of Amyloid-β 13 1.4.1 Familial mutations, A21, E22, and D23, in Alzheimer’s disease 13 1.4.2 N-terminal familial mutations, H6 and D7, in Alzheimer’s disease 15 1.5 Application of nanotechnology in the studies of Alzheimer’s disease 16 Chapter 2 Materials and methods 18 2.1 Materials 18 2.2 Methods 18 2.2.1 Aβ monomer preparation 18 2.2.2 AuNPs preparation 20 2.2.3 Thioflavin T assay 21 2.2.4 Dynamic light scattering 21 2.2.5 Transmission electron microscopy 22 2.2.6 Fourier transform infrared spectroscopy 22 2.2.7 Far-UV circular dichroism spectroscopy 23 2.2.8 Fluorescence lifetime measurement 23 2.2.9 Stopped-flow fluorescence 24 2.2.10 Fluorescence spectroscopy 25 2.2.11 Proton and 1H-15N HSQC NMR spectroscopy 25 Chapter 3 Interference of gold nanoparticles in the fibrillization process of wild type Aβ40.......... 27 3.1 Aims 27 3.2 Bare AuNPs inhibit Aβ fibrillization without self-clustering 28 3.3 Bare AuNPs alter ThT fluorescence intensity of preformed Aβ fibrils 31 3.4 Absorbance spectra of Aβ monomers or preformed Aβ fibrils 33 3.5 DLS analysis shows redirected Aβ species in the presence of AuNPs 35 3.6 Bare AuNPs induce Aβ fibril fragmentation and oligomer formation and preferentially bind to Aβ fibrils 37 3.7 Negatively charged AuNPs inhibit Aβ fibrillization in vitro 40 Chapter 4 Structural differences between homo-polymeric and hetero-polymeric Aβ fibrils.......... 43 4.1 Aims 43 4.2 Homo- and hetero- fibrils are morphologically indistinguishable under TEM imaging. 44 4.3 Binding stoichiometry of Thioflavin T to amyloid-β fibrils 46 4.4 Secondary structures of fibrils revealed by far-UV circular dichroism 48 4.5 Secondary structures of fibrils revealed by Fourier transformation infrared spectroscopy 52 4.6 Fluorescence lifetime of bound ThT on fibrils 57 Chapter 5 Interactions of Cu2+ with wild type and N-terminal familial mutants of Aβ 62 5.1 Aims 62 5.2 Metal ion binding examined by stopped-flow fluorescence. 62 5.3 Intrinsic fluorescence of H6 and D7 mutants upon Cu2+ binding 65 5.4 Bis-ANS fluorescence of H6 and D7 mutants upon Cu2+ binding 68 5.5 1H NMR spectroscopy 72 5.6 1H-15N HSQC spectroscopy of D7H and wild type Aβ 78 Chapter 6 Discussion 84 6.1 Negatively Charged Gold Nanoparticles Inhibit Alzheimer’s Amyloid-β Fibrillization, Induce Fibril Dissociation, and Mitigate Neurotoxicity 84 6.1.1 Results of various effects imposed by AuNPs on Aβ 84 6.1.2 Inhibition of Aβ fibrillization by nanoparticles 87 6.1.3 Effect of localized charge on Aβ fibrillization 88 6.2 Homo- and hetero- polymeric Aβ fibrils 91 6.3 Cu2+ coordination of H6 and D7 mutants of Aβ 92 6.3.1 Effect of H6 mutation on Cu2+ binding to Aβ 94 6.3.2 Effect of D7 mutation on Cu2+ binding to Aβ 95 Reference... 97 Supplementary data 108 | |
dc.language.iso | en | |
dc.title | 透過金屬離子結合、家族性突變型、以及奈米金粒子瞭解阿茲海默症乙型類澱粉蛋白纖維化的複雜性 | zh_TW |
dc.title | Understanding the Complexity of Alzheimer’s Disease’s Amyloid-β Fibrillization via Metal Ion Binding, Familial Mutants, and Gold Nanoparticles | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 蔡明道(Ming-Daw Tsai) | |
dc.contributor.oralexamcommittee | 陳振中(Jerry Chun Chung Chan),陳佩燁(Rita Pei-Yeh Chen),林俊成(Chun-Cheng Lin),王勝仕(Sheng-Shih Wang) | |
dc.subject.keyword | 阿茲海默症,乙型類澱粉蛋白,類澱粉蛋白纖維,家族性突變型,金屬離子,奈米金粒子, | zh_TW |
dc.subject.keyword | Amyloid-beta,Amyloid fibril,Familial mutation,Metal ions,Gold nanoparticles, | en |
dc.relation.page | 109 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-08-12 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科學研究所 | zh_TW |
顯示於系所單位: | 生化科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 4.22 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。